Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 2Rectal Neoplasms 1Ovarian Neoplasms 1Melanoma 1HIV Infections 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Anus Neoplasms 1

Interventions

Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Radiotherapy 3Mitomycin 3Fluorouracil 3Biopsy 3fludarabine phosphate 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Sigmoidoscopy 2Proctoscopy 2Ipilimumab 2Interleukin-12 Subunit p35 2Erlotinib Hydrochloride 2Cyclophosphamide 2Colonoscopy 2CTLA-4 Antigen 2tipifarnib 1tempol 1oncogene protein E7, Human papillomavirus type 16 1dehydroftorafur 1bintrafusp alfa protein, human 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Taxes 1Serotonin Plasma Membrane Transport Proteins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anus Neoplasms × Sentinel Lymph Node Biopsy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡